EZH2表位肽在多发性骨髓瘤中的预测和验证  

Prediction and Validation of EZH2 Epitopic Peptide in Multiple Myeloma

作　　者：钟赟 刘哲[1] ZHONG Yun;LIU Zhe(Jiangxi Cancer Hospital,Nanchang,330029)

机构地区：[1]江西省肿瘤医院,330006

出　　处：《实用癌症杂志》2021年第12期1935-1938,共4页The Practical Journal of Cancer

基　　金：江西省卫生计生委课题(编号:20181115)。

摘　　要：目的预测出一种新型的EZH2蛋白表位肽,验证其在多发性骨髓瘤患者中的表达,从而为EZH2表位肽作为MM治疗的靶点运用于临床工作奠定基础。方法首先应用生物信息软件筛选EZH2高积分肽段,同时通过T2细胞实验进一步筛选出具备高亲和力及稳定性的一条肽段,进一步验证该表位肽是生理和病理情况下都存在的。结果通过本研究,预测出一种新型的EZH2特异性肽段YMCSFLFNL在多发性骨髓瘤和健康供者中存在,且明显高于健康供者。结论EZH2表位肽可以作为多发性骨髓瘤免疫治疗的靶点。Objective To predict a novel EZH2 protein epitope peptide and verify its expression in patients with multiple myeloma,thus laying a foundation for the clinical application of EZH2 protein epitope peptide as the target of MM therapy.Methods Bioinformatics software was used to screen EZH2 high-integrating peptide.A peptide with high affinity and stability was further screened by T2 cell assay to further verify that the epitope peptide existed in both physiological and pathological conditions.Results A novel EZH2-specific peptide YMCSFLFNL was predicted to be present in multiple myeloma and healthy donors,and was significantly higher than that in healthy donors.Conclusion EZH2 epitopes can be used as immunotherapy targets for multiple myeloma.

关 键 词：EZH2 表位肽 多发性骨髓瘤 

分 类 号：R733.3[医药卫生—肿瘤]